2026-08-20 マウントサイナイ医療システム（MSHS）
＜関連情報＞
- https://www.mountsinai.org/about/newsroom/2026/mount-sinai-study-finds-chemotherapy-free-treatment-shows-promise-for-some-patients-with-metastatic-breast-cancer
- https://academic.oup.com/jnci/advance-article-abstract/doi/10.1093/jnci/djag256/8747623
ホルモン受容体（HR）陽性、HER2陽性転移性乳がん患者を対象とした、アナストロゾール、パルボシクリブ、トラスツズマブ、およびペルツズマブの併用療法に関する多施設共同第I/II相臨床試験（ASPIRE） A multicenter, phase I/II trial of anastrozole, palbociclib, trastuzumab, and pertuzumab in hormone receptor (HR)-positive, HER2-positive metastatic breast cancer (ASPIRE)
Rima Patel, MD,Maryann Kwa, MD,Paula Klein, MD,Julie Fasano, MD,Erin Moshier, BS,Hulya Kocyigit, Ph.D,Anupama Goel, MD,Melissa Accordino, MD,Charles Shapiro, M ,Rita Vaccaro, RN,…
Journal of the National Cancer Institute Published:30 July 2026
DOI:https://doi.org/10.1093/jnci/djag256
Abstract
Purpose
The ASPIRE trial evaluated frontline anastrozole, palbociclib, trastuzumab, and pertuzumab in patients with HR-positive, HER2-positive metastatic breast cancer (MBC).
Methods
This phase I/II trial enrolled patients with previously untreated, HR-positive, HER2-positive MBC. In Phase I, patients received escalating doses of palbociclib with trastuzumab, pertuzumab and anastrozole, using a 3 + 3 dose escalation design, and primary endpoint was maximum tolerated dose (MTD). Phase II followed an optimal Simon two-stage design where all patients received palbociclib at the MTD, plus anastrozole, trastuzumab, and pertuzumab and the primary endpoint was clinical benefit rate (CBR) in the first six months. Secondary endpoints included progression free survival (PFS), overall survival (OS) and safety.
Results
In Phase I, no dose limiting toxicities were observed at the 100mg (N = 3) or 125mg (N = 6) dose levels, and thus, 125mg was the MTD. An additional 23 patients were enrolled to Phase II, with a total of 29 patients in the response-evaluable population. The primary endpoint of CBR was 97% (N = 28; 95% CI: 82-99%). At a median follow-up of 45.3 months, median PFS was 24.9 months (95% CI: 17.2-44.8). Median OS was not reached at a follow-up of 39.4 months. Most common treatment-related adverse events (TRAEs) were neutropenia, leukopenia, diarrhea, and anemia. Grade 3-4 TRAEs occurred in 62% (N = 18) of patients and most were hematologic.
Conclusions
The combination of anastrozole, palbociclib, trastuzumab, and pertuzumab demonstrated promising activity in this single-arm trial of patients with HR-positive, HER2-positive MBC and warrants further study in randomized trials. The regimen could provide a chemotherapy-free alternative.
